Back to results
US 11,518,796 B2Granted
Engineered platelets for targeted delivery of a therapeutic agent
OwnerJames Pattersoninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets.
Claims15
An engineered megakaryocyte or megakaryocyte progenitor cell line that produces platelets with reduced thrombogenic potential, comprising a disruption of or deletion of at least two genes encoding:
- (a) a protein involved in recognition of primary stimuli of thrombus formation selected from the group consisting of:
- GPIb/V/IX, GPVI (GP6), ITGA2B, CLEC2, integrins αIIbβ3, α2β1, α5β1 and/or α6β1;
- (b) a protein involved in recognition of secondary mediators of thrombus formation selected from the group consisting of Par1, Par4, P2Y12, GPIb/V/IX, the Thromboxane receptor (TBXA2R), P2Y1, P2X1 and/or integrin αIIbβ3;
- and/or
- (c) a protein involved in the release of secondary mediators of thrombus formation selected from the group consisting of Cox1, HPS and/or thromboxane-A synthase (TBXAS1).
2 more elements
Dependencies are inferred from the claim text.